Novel 6-phenlyphenanthridines

1 . A compound of the formula I,

in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl, p 1 or in which R3 and R31 together are a 1-4C-alkylene group,

R4 is hydrogen or 1-4C-alkyl,

R5 is hydrogen,

R51 is hydrogen,

or in which R5 and R51 together represent an additional bond,

R6 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R7 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, pyridinyl, phenyl or R71- and/or R72-substituted phenyl, wherein

R71 is halogen, hydroxyl, cyano, trifluoromethyl, carboxyl, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R72 is 1-4C-alkoxy, 1-4C-alkyl or halogen,

R8 is hydrogen, phenyl, 1-4C-alkyl, aryloxy-2-4C-alkyl or R9-substituted 1-4C-alkyl, wherein

aryloxy is phenoxy or R81-substituted phenoxy, wherein

R81 is halogen or trifluoromethyl,

R9 is phenyl, C(O)N(R91)R92 or R93-substituted phenyl, wherein

R91 is phenyl, aryl-1-4C-alkyl or R911-substituted phenyl, wherein

aryl is phenyl or R81-substituted phenyl,

R911 is 1-4C-alkoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R92 is hydrogen,

or wherein R91 and R92, together and including the nitrogen atom to which both are bound, represent a 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, 1-hexahydroazepinyl or 4-morpholinyl radical,

R93 is nitro, 1-4C-alkyl, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl, 1-4C-alkoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or a salt or an E/Z isomer thereof.

2 . A compound of the formula I as claimed in claim 1 , in which

R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted l-2C-alkoxy,

R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is hydrogen or 1-2C-alkyl,

R5 is hydrogen,

R51 is hydrogen,

or in which R5 and R51 together represent an additional bond,

R6 is hydrogen,

R7 is 1-4C-alkyl or phenyl,

R8 is hydrogen, phenyl, 1-4C-alkyl, aryloxy-2-4C-alkyl or R9-substituted 1-2C-alkyl, wherein

aryloxy is phenoxy or R81-substituted phenoxy, wherein

R81 is halogen or trifluoromethyl,

R9 is phenyl, C(O)N(R91)R92 or R93-substituted phenyl, wherein

R91 is aryl-1-2C-alkyl or R911-substituted phenyl, wherein

aryl is phenyl or R81-substituted phenyl,

R911 is 1-4C-alkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R92 is hydrogen,

or wherein R91 and R92, together and including the nitrogen atom to which both are bound, represent a 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl or 4-morpholinyl radical,

R93 is nitro, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl, 1-4C-alkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,

or a salt or an E/Z isomer thereof.

3 . A compound of the formula I as claimed in claim 1 , in which

R1 is methoxy,

R2 is methoxy,

R3, R31, R4, R5 and R51 are hydrogen,

R6 is hydrogen,

R7 is 1-2C-alkyl or phenyl,

R8 is hydrogen, phenyl, methyl, ethyl, isobutyl, aryloxyethyl or R9-substituted methyl, wherein

aryloxy is phenoxy or R81-substituted phenoxy, wherein

R81 is trifluoromethyl,

R9 is phenyl, C(O)N(R91)R92 or R93-substituted phenyl, wherein

R91 is arylmethyl or R911-substituted phenyl, wherein

aryl is chlorine-substituted phenyl,

R911 is methoxy,

R92 is hydrogen,

or wherein R91 and R92, together and including the nitrogen atom to which both are bound, represent a 4-phenylpiperazin-1-yl or 4-morpholinyl radical,

R93 is nitro, methoxycarbonyl, chloro, fluoro, trifluoromethyl or methoxy,

or a salt or an E/Z isomer thereof.

4 . A compound of the formula I as claimed in claim 1 , in which either

R1 is methoxy,

R2 is methoxy,

R3, R31, R4, R5 and R51 are hydrogen,

R6 is hydrogen,

R7 is methyl,

R8 is hydrogen, phenyl, methyl, ethyl, isobutyl, phenoxyethyl, 3-trifluoromethylphenoxyethyl or R9-substituted methyl, wherein

R9 is phenyl, 4-nitrophenyl, 4-methoxycarbonylphenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-fluorophenyl, 3-fluorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-methoxyphenyl, 2-methoxyphenyl or C(O)N(R91)R92, wherein

R91 is 2-methoxyphenyl or 4-chlorobenzyl,

R92 is hydrogen,

or wherein R91 and R92, together and including the nitrogen atom to which both are bound, represent a 4-phenylpiperazin-1-yl or 4-morpholinyl radical;

or

R1 is methoxy,

R2 is methoxy,

R3, R31, R4, R5 and R51 are hydrogen,

R6 is hydrogen,

R7 is phenyl,

R8 is hydrogen;

or a salt or an E/Z isomer thereof

5 . A compound of the formula I according to claim 1 , in which the hydrogen atoms in positions 4 a and 10 b are in the cis position relative to one another, or a salt or an E/Z isomer thereof.

6 . A compound of the formula I according to claim 1 , which have with respect to the positions 4a and 10b the configuration shown in formula I*:

or a salt or an E/Z isomer thereof.

7 . (canceled)

8 . A pharmaceutical composition comprising one or more compounds of the formula I as claimed in claim 1 together with a pharmaceutically acceptable excipient or vehicle.

9 . (canceled)

10 . A method for treating a respiratory disorder or dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of the formula I as claimed in claim 1 .

11 . A method for treating an airway disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of the formula I as claimed in claim 1.